Across TCGA pan-cancer cohorts, RNU6-663P RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RNU6-663P data layer.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNU6-663P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-663P expression acts as an unfavorable survival marker, although some lineages such as OV and LUAD show a favorable association.
LIHC, STAD, and READ are the cancer types where RNU6-663P RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.